EL
ELTX.US Elicio Therapeutics Inc.
- Market cap
- USD 42.5M
- P/E
- -
- P/B
- 2.34x
- ROE
- -198.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ELTX.US undervalued?
Graham numberThe Graham number of Elicio Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Elicio Therapeutics Inc. fundamental analysis
No fundamental analysis for Elicio Therapeutics Inc. yet.
Elicio Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolo…
Full company profileElicio Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Elicio Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.30M | 6.58M | 4.03M | 1.49M | 2.88M | 28.3M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.62M | 3.41M | 3.65M | 351K | 1.06M | 27.1M | -1.06M | -1.17M | -1.18M | -1.13M | - |
| Operating Income | -419K | -398K | -14.3M | -38.6M | -55.3M | -39.3M | -23.7M | -35.7M | -45.0M | -37.7M | -39.3M |
| EBITDA | 1.96M | 62.5K | -14.3M | -40.2M | -70.6M | -52.5M | -23.6M | -33.0M | -50.3M | -37.3M | -41.6M |
| Net Income | 307K | 632K | -20.0M | -40.7M | -80.1M | -26.4M | -28.2M | -35.2M | -51.9M | -39.6M | -37.4M |
| EPS | 50 | 103 | -6.79 | -4.99 | -9.83 | -8.25 | -9.10 | -6.96 | -4.25 | -2.58 | -1.42 |
| Balance Sheet | |||||||||||
| Total Assets | 11.0M | 11.1M | 26.6M | 11.9M | 47.3M | 96.5M | 22.7M | 27.1M | 28.2M | 25.9M | 39.6M |
| Total Liabilities | 6.79M | 6.60M | 7.72M | 30.5M | 138M | 15.0M | 13.7M | 15.8M | 39.5M | 24.2M | 20.7M |
| Shareholders' Equity | 1.71M | 2.34M | 18.9M | -18.6M | -90.4M | 81.5M | 8.92M | 11.4M | -11.3M | 1.64M | 18.9M |
| Cash & Short-term Investments | 1.40M | 2.06M | 25.5M | 5.57M | 34.6M | 88.8M | 7.80M | 12.9M | 17.6M | 18.6M | 30.9M |
| Total Debt | 5.44M | 5.32M | - | 10.8M | 85.0M | 4.66M | 7.48M | 6.92M | 26.0M | 14.5M | 14.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.07M | 1.89M | -8.02M | -24.6M | -22.9M | -23.9M | -22.2M | -32.7M | -37.1M | -37.0M | -40.2M |
| Capital Expenditure | 47.7K | 17.6K | 0.00 | 242K | 41.0K | 525K | 654K | 66.0K | 87.0K | 16.0K | 0.00 |
| Free Cash Flow | 1.02M | 1.87M | -8.02M | -24.8M | -22.9M | -24.5M | -22.8M | -32.8M | -37.2M | -37.0M | -40.2M |
| Ratios | |||||||||||
| ROE | 18.0% | 27.0% | -105.9% | - | - | -32.4% | -316.4% | -309.5% | - | -2,418.8% | -198.2% |
| ROA | 2.8% | 5.7% | -75.2% | -342.1% | -169.2% | -27.4% | -124.5% | -129.7% | -184.2% | -153.0% | -94.3% |
| Net Profit Margin | 4.2% | 9.6% | -497.0% | -2,734.2% | -2,781.5% | -93.2% | - | - | - | - | - |
| Debt to Equity | 3.18x | 2.27x | - | - | - | 0.06x | 0.84x | 0.61x | - | 8.87x | 0.74x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Elicio Therapeutics Inc. dividends
Elicio Therapeutics Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jun 2, 2023.
Who owns Elicio Therapeutics Inc.
- Insiders 25.86%
- Institutions 22.60%
- Public & others 51.54%
- Shares outstanding 28.3M
- Free float 21.2M
Top funds holding ELTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 415K | 1.47% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 312K | 1.10% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 145K | 0.51% | +4.05% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 123K | 0.43% | -0.38% | Oct 2026 |
| Abante Quant Value FI | 120K | 0.42% | +93.25% | Aug 2026 |
| Vanguard Russell 2000 ETF | 93.9K | 0.33% | +24.05% | Sep 2026 |
| Fidelity Extended Market Index | 78.6K | 0.28% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 48.0K | 0.17% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 47.8K | 0.17% | 0.00% | Oct 2026 |
| EQ/AB Small Cap Growth IB | 40.6K | 0.14% | 0.00% | Sep 2026 |
| EQ/Small Company Index IB | 40.6K | 0.14% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 31.7K | 0.11% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 29.4K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 21.3K | 0.08% | 0.00% | Sep 2026 |
| Vifag 2002 SICAV | 20.0K | 0.07% | -83.25% | Sep 2026 |
| Fidelity Series Total Market Index | 18.2K | 0.06% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 17.9K | 0.06% | 0.00% | Aug 2026 |
| EQ/2000 Managed Volatility IB | 16.4K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth Index | 15.2K | 0.05% | -5.61% | Aug 2026 |
| Vanguard Russell 2000 Growth ETF | 14.1K | 0.05% | +0.06% | Sep 2026 |
Top institutions holding ELTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Shah Capital Management | 1.25M | 4.61% | 0.00% | Sep 2026 |
| Knoll Capital Management LP | 1.21M | 4.47% | +92.10% | Jun 2026 |
| BlackRock Inc | 766K | 2.83% | +1,413.93% | Jun 2026 |
| Vanguard Capital Management, LLC | 572K | 2.11% | +10.32% | Jun 2026 |
| Geode Capital Management, LLC | 311K | 1.15% | +130.35% | Jun 2026 |
| State Street Corp | 179K | 0.66% | +254.44% | Jun 2026 |
| Northern Trust Corp | 130K | 0.48% | +117.90% | Jun 2026 |
| Ikarian Capital, LLC | 100K | 0.37% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 88.9K | 0.33% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 88.1K | 0.33% | +27.28% | Jun 2026 |
| AllianceBernstein L.P. | 81.3K | 0.30% | 0.00% | Jun 2026 |
| UBS Group AG | 40.4K | 0.15% | +19.69% | Jun 2026 |
| Charles Schwab Investment Management Inc | 31.7K | 0.12% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 30.7K | 0.11% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 25.5K | 0.09% | -21.16% | Jun 2026 |
| LEONTEQ SECURITIES AG | 20.0K | 0.07% | 0.00% | Jun 2026 |
| Nuveen, LLC | 17.9K | 0.07% | 0.00% | Jun 2026 |
| Citigroup Inc | 17.7K | 0.07% | 0.00% | Jun 2026 |
| Bank of New York Mellon Corp | 15.9K | 0.06% | 0.00% | Jun 2026 |
| New York State Common Retirement Fund | 14.2K | 0.05% | 0.00% | Jun 2026 |
Elicio Therapeutics Inc. company profile
- Company name
- Elicio Therapeutics Inc.
- Ticker
- ELTX.US
- Exchange
- USA Stocks
- Listed since
- Feb 5, 2021
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 33
- Fiscal year end
- December
- Address
- 451 D Street, Boston, MA, United States, 02210
- Phone
- 857 209 0050
- Website
- elicio.com
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Elicio Therapeutics Inc. management
10- Mr. Robert T. ConnellyCEO, President & Director · born 1960
- Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.Founder & Independent Director · born 1947
- Dr. Preetam Shah M.B.A., Ph.D.Chief Strategy & Financial Officer and Treasurer · born 1973
- Dr. Christopher M. Haqq M.D., Ph.D.Executive VP, Head of Research & Development and Chief Medical Officer · born 1966
- Dr. Darrell J. Irvine Ph.D.Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
- Mr. Marc J. Wolfgang M.S.Chief Technology Officer
- Dr. Peter DeMuth Ph.D.Chief Scientific Officer · born 1987
- Ms. Megan C. FiloonGeneral Counsel, Secretary & Compliance Officer
- Ms. Esther WelkowskySenior Vice President of Clinical Development
- Ms. Joy SeymourSenior VP & Head of Regulatory Affairs